SRD5A3-AS1: A Potential Drug Target and Biomarker (G100506462)

Target Name: SRD5A3-AS1

NCBI ID: G100506462

SRD5A3-AS1

Other Name(s): SRD5A3 antisense RNA 1

SRD5A3-AS1: A Potential Drug Target and Biomarker

SRD5A3-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug candidate has generated a lot of interest in the scientific community.

The SRD5A3-AS1 molecule is a part of the SRD5A3 gene family, which is known to encode a protein involved in the regulation of mitochondrial dynamics and energy metabolism. The protein encoded by this gene is composed of 183 amino acids and has a molecular weight of 20 kDa. It is located in the mitochondrial protein pool and is involved in the regulation of various cellular processes, including the transport of nutrients, the production of reactive oxygen species, and the control of mitochondrial dynamics.

Recent studies have suggested that SRD5A3-AS1 may have a variety of functions, including the regulation of cell growth, cell survival, and cell death. It has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

One of the key features of SRD5A3-AS1 is its ability to interact with various signaling pathways, including TOR, PI3K, and NF-kappa-B. These signaling pathways are involved in various cellular processes, including cell growth, cell survival, and cell death. By interacting with these signaling pathways, SRD5A3-AS1 has been shown to promote the growth and survival of various cell types, including cancer cells, neurodegenerative disease cells, and brain cells.

In addition to its role in cell survival, SRD5A3-AS1 has also been shown to play a role in the regulation of cellular processes that are important for proper brain function. It has been shown to be involved in the production of neurotransmitters, such as dopamine and serotonin, which are involved in mood regulation, attention, and other cognitive processes. It has also been shown to play a role in the regulation of ion channels, including the Na+/K+ATPase, which is involved in the regulation of ion movement and neurotransmitter release.

Given its potential role in various cellular processes, SRD5A3-AS1 has generated a lot of interest as a drug target. Many researchers are actively searching for small molecules that can interact with SRD5A3-AS1 and enhance its function as a drug candidate. In addition to its potential as a drug target, SRD5A3-AS1 has also been identified as a potential biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

The identification of SRD5A3-AS1 as a potential drug target and biomarker has important implications for the development of new treatments for a variety of diseases. By targeting SRD5A3-AS1 with small molecules or other therapeutic agents, researchers may be able to enhance its function as a drug and improve treatment outcomes for a variety of diseases.

In conclusion, SRD5A3-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug candidate has generated a lot of interest in the scientific community. Further studies are needed to fully understand its role in various cellular processes and its potential as a drug target and biomarker.

Protein Name: SRD5A3 Antisense RNA 1

The "SRD5A3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SRD5A3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets